Clinical trials: First Line Treatment
Colorectal Cancer, Immunotherapy
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.
- Conditions
- Colorectal Cancer, Immunotherapy, Anlotinib, Sintilimab
- Trial name
- NCT04271813
- Testing
- Anlotinib plus Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Advanced Lung Carcinoma, First Line Treatment
Exercise in Patients With Advanced Non-small Cell Lung Cancer
Lung cancer is one of the most common types of cancer in Germany, with 56,839 new cases and 45,072 deaths annually. Approximately 70% of patients with non-small cell lung cancer (NSCLC) are diagnosed at an advanced stage and…
- Conditions
- Advanced Lung Carcinoma, First Line Treatment, Second Line Treatment, NSCLC Stage IV
- Trial name
- BREATH (NCT06374160)
- Testing
- Exercise intervention
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- University Hospital, Essen
HER2-positive Metastatic Breast Cancer, First-line Treatment
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
The goal of this multicentre, randomized, double-blind controlled, phase III clinical trial is to compare the efficacy and safety of disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of…
- Trial name
- NCT06278870
- Testing
- disitamab vedotin, Pyrotinib, trastuzumab
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Carcinoma, Intrahepatic Cholangiocarcinoma
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients…
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor
- Trial name
- NCT05913661
- Testing
- Pemigatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Toripalimab, First-line Treatment
Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma
This study is a prospective, multicenter, open-label, single-arm phase II clinical trial. A single-arm experimental group of toripalimab, etoposide, and cisplatin/carboplatin was designed to evaluate its efficacy and safety in…
- Trial name
- NCT05760053
- Testing
- EP/EC+PD-1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sun Yat-sen University
Gallbladder Cancer, Initially Unresectable
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Study design: Prospective, single-arm, single-center phase II clinical study; Primary endpoint: Objective response rate via investigator, Safety; Secondary endpoints: disease control rate, disease-free survival, overall survival…
- Conditions
- Gallbladder Cancer, Initially Unresectable, the First Line Treatment
- Trial name
- NCT05757336
- Testing
- Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Lu Wang, MD, PhD
AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
In this multicenter, upfront randomized phase II trial, all patients receive quizartinib in combination with HAM (high-dose cytarabine, mitoxantrone) during salvage therapy.
- Trial name
- Q-HAM (NCT03989713)
- Testing
- MRD-triggered arm, Prophylactic Arm
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Prof. Dr. Richard F Schlenk
Local Progression or Metastatic Melanoma With Failed First-line Treatment
Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma
The study will be divided into two stages: phase Ib and phase II. The safety and phase II recommended dose (RP2D) of Pexa-Vec combined with ZKAB001 in patients with local progression of failed first-line treatment or metastatic…
- Trial name
- NCT04849260
- Testing
- Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Lee's Pharmaceutical Limited
First-line Treatment, Advanced Gastric Carcinoma
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
This is a single center, prospective, open label phase I study evaluating the safety and tolerance of standard first-line chemotherapy XELOX regimen combined with GLS-010 (anti-PD-1 antibody) and different doses of Lenvatinib in…
- Trial name
- NCT05221775
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
First-line Treatment, Advanced Colorectal Cancer
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
This is a two-group, parallel, randomized, standard-control phase II study comparing the safety and efficacy of trifluridine/tipiracil combined with oxaliplatin and bevacizumab versus XELOX plus bevacizumab in the first-line…
- Trial name
- TOBACO (NCT05077839)
- Testing
- Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or
Chemotherapy for Patients With Cancer of the Stomach
The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.
- Trial name
- DOS (NCT01928524)
- Testing
- DOS2w Dose level 1A, DOS2w Dose level 2A, DOS2w Dose level 3A
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Per Pfeiffer
Non-small Cell Lung Cancer, First-line Treatment
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
This prospective, unicentric, open-labe phase I study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of…
- Trial name
- NCT03987867
- Testing
- CIK cell, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Non-small Cell Lung Cancer, First Line Treatment
Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
In pre-clinical study we found that the thioredoxin reductase activity of serum harbours huge difference between cancer patients and non-cancer patients, the enzyme activity elevated remarkably among cancer patients, and after…
- Conditions
- Advanced Non-small Cell Lung Cancer, First Line Treatment, Thioredoxin Reductase Activity, Carcinoembryonic Antigen
- Trial name
- NCT01980212
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Hunan Province Tumor Hospital
Advanced NSCLC, First Line Treatment
POSITIVE - Study (Part III) Heidelberg
The investigators plan to evaluate, in a randomized, controlled phase III trial in patients with advanced non-small cell lung cancer (NSCLC), the effects of a 24-week exercise intervention program (EIP) on quality of life…
- Trial name
- POSITIVE (NCT02055508)
- Testing
- Exercise Intervention, Care-Management-Phone-Calls
- Where
- Germany
- Volunteers
- 232 people
- Sponsor
- German Cancer Research Center
Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.
Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line
Evaluate the effectiveness of rituximab, bendamustine (r) in terms of complete response and response complete not confirmed.
- Trial name
- NCT01127841
- Testing
- Rituximab and Bendamustine
- Where
- 18 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas